CA3014196A1 - Antigen for use in malaria vaccine - Google Patents

Antigen for use in malaria vaccine Download PDF

Info

Publication number: CA3014196A1
Authority: CA; Canada
Prior art keywords: seq; mice; derivatives; mammal; virus
Prior art date: 2016-02-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CA3014196A

Other languages

English (en)

French (fr)

Inventor

Joao Carlos Aguiar

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Camris International Inc

Original Assignee

Camris International Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-02-17

Filing date

2017-02-13

Publication date

2017-08-24

2017-02-13 Application filed by Camris International Inc filed Critical Camris International Inc

2017-08-24 Publication of CA3014196A1 publication Critical patent/CA3014196A1/en

Status Pending legal-status Critical Current

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Tropical Medicine & Parasitology (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Mycology (AREA)
Epidemiology (AREA)
Microbiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA3014196A 2016-02-17 2017-02-13 Antigen for use in malaria vaccine Pending CA3014196A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662296464P	2016-02-17	2016-02-17
US62/296,464		2016-02-17
PCT/US2017/017722 WO2017142843A1 (en)	2016-02-17	2017-02-13	Novel antigen for use in malaria vaccine

Publications (1)

Publication Number	Publication Date
CA3014196A1 true CA3014196A1 (en)	2017-08-24

Family

ID=59559460

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA3014196A Pending CA3014196A1 (en)	2016-02-17	2017-02-13	Antigen for use in malaria vaccine

Country Status (10)

Country	Link
US (2)	US10195260B2 (2)
EP (1)	EP3416681B1 (2)
JP (2)	JP7261013B2 (2)
KR (1)	KR20180108754A (2)
CN (1)	CN109069607A (2)
AU (1)	AU2017219613B2 (2)
BR (1)	BR112018016912A2 (2)
CA (1)	CA3014196A1 (2)
WO (1)	WO2017142843A1 (2)
ZA (1)	ZA201805547B (2)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3416681B1 (en)	2016-02-17	2026-01-21	DayLife LLC	Novel antigen for use in malaria vaccine
CN110703326B (zh) *	2019-10-11	2021-07-16	中国石油化工股份有限公司	一种基于中小偏移距道集的fvo反演方法
US12485166B2 (en)	2020-02-06	2025-12-02	Longhorn Vaccines And Diagnostics, Llc	Vaccines for the treatment and prevention of zoonotic infections
WO2022003999A1 (en) *	2020-06-29	2022-01-06	Path	Pre-erythrocytic malaria vaccines
KR20230091978A (ko)	2020-10-20	2023-06-23	롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨	면역원성 항원
EP4590331A1 (en)	2022-09-23	2025-07-30	BioNTech SE	Compositions for delivery of plasmodium csp antigens and related methods
WO2024063788A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of malaria antigens and related methods
JP2025533541A (ja)	2022-09-23	2025-10-07	ビオンテック・ソシエタス・エウロパエア	肝病期抗原の送達のための組成物及び関連方法
WO2024063789A1 (en)	2022-09-23	2024-03-28	BioNTech SE	Compositions for delivery of malaria antigens and related methods
EP4669348A1 (en)	2023-02-24	2025-12-31	BioNTech SE	IMMUNOGENEOUS COMPOSITIONS
CN121816193A (zh)	2023-07-21	2026-04-07	生物技术欧洲股份公司	用于递送疟原虫抗原的组合物及相关方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101863970B (zh) *	2010-05-18	2012-09-12	吉林大学	一种可抑制恶性疟原虫侵入的抗Pf332-DBL区单克隆抗体
US9884101B2 (en) *	2010-11-09	2018-02-06	The Walter And Eliza Hall Institute For Medical Research	Treatment and prevention of malaria
WO2013108272A2 (en) *	2012-01-20	2013-07-25	International Centre For Genetic Engineering And Biotechnology	Blood stage malaria vaccine
GB201318084D0 (en)	2013-10-11	2013-11-27	Isis Innovation	Malaria vaccination
EP3416681B1 (en)	2016-02-17	2026-01-21	DayLife LLC	Novel antigen for use in malaria vaccine

2017
- 2017-02-13 EP EP17753691.9A patent/EP3416681B1/en active Active
- 2017-02-13 AU AU2017219613A patent/AU2017219613B2/en active Active
- 2017-02-13 CN CN201780012190.0A patent/CN109069607A/zh active Pending
- 2017-02-13 BR BR112018016912A patent/BR112018016912A2/pt not_active Application Discontinuation
- 2017-02-13 WO PCT/US2017/017722 patent/WO2017142843A1/en not_active Ceased
- 2017-02-13 US US15/431,609 patent/US10195260B2/en active Active
- 2017-02-13 JP JP2018544178A patent/JP7261013B2/ja active Active
- 2017-02-13 CA CA3014196A patent/CA3014196A1/en active Pending
- 2017-02-13 KR KR1020187024980A patent/KR20180108754A/ko active Pending
2018
- 2018-08-20 ZA ZA2018/05547A patent/ZA201805547B/en unknown
- 2018-12-21 US US16/230,512 patent/US11793868B2/en active Active
2021
- 2021-12-10 JP JP2021200524A patent/JP2022037078A/ja active Pending

Also Published As

Publication number	Publication date
JP2019505560A (ja)	2019-02-28
JP2022037078A (ja)	2022-03-08
US20170232091A1 (en)	2017-08-17
WO2017142843A8 (en)	2018-09-07
CN109069607A (zh)	2018-12-21
EP3416681B1 (en)	2026-01-21
EP3416681A1 (en)	2018-12-26
AU2017219613B2 (en)	2022-04-07
JP7261013B2 (ja)	2023-04-19
US10195260B2 (en)	2019-02-05
US20190117752A1 (en)	2019-04-25
AU2017219613A1 (en)	2018-08-30
EP3416681A4 (en)	2020-03-18
ZA201805547B (en)	2023-01-25
KR20180108754A (ko)	2018-10-04
BR112018016912A2 (pt)	2018-12-26
WO2017142843A1 (en)	2017-08-24
US11793868B2 (en)	2023-10-24

Legal Events

Date	Code	Title	Description
2022-03-18	EEER	Examination request	Effective date: 20220211
2024-10-10	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241010
2024-12-21	MFA	Maintenance fee for application paid	Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8
2024-12-21	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241221
2024-12-21	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241221 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241221
2025-01-02	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250102
2025-05-13	P11	Amendment of application requested	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250513
2025-05-13	P13	Application amended	Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250513
2025-12-17	MFA	Maintenance fee for application paid	Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9
2025-12-17	U00	Fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251217
2025-12-17	U11	Full renewal or maintenance fee paid	Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251217
2026-02-18	D22	Grant of ip right intended	Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260218
2026-02-18	W00	Other event occurred	Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260218

Publication	Publication Date	Title
US11793868B2 (en)	2023-10-24	Antigen for use in malaria
JP5108521B2 (ja)	2012-12-26	マラリア初回免疫／追加免疫ワクチン
EP2277533B1 (en)	2016-07-20	Methods for vaccinating against malaria
JP2008544969A (ja)	2008-12-11	抗マラリアワクチン
HK40001561A (en)	2020-02-28	Novel antigen for use in malaria vaccine
HK40001561B (en)	2026-03-27	Novel antigen for use in malaria vaccine
CN100333791C (zh)	2007-08-29	抗疟疾的疫苗接种方法
Dhanawat et al.	2010	Development in malarial vaccine: A review.
Nardin	1999	16 Synthetic Peptides as Malaria Vaccines
HK1153412A (en)	2012-03-30	Methods for vaccinating against malaria
HK1100121B (en)	2012-07-06	Malaria prime/boost vaccines